- S&P 5007,561.67−0.40%
- Nasdaq 10027,943.74−1.22%
- NVDA$162.85−2.01%
- AAPL$356.27+0.39%
- MSFT$523.88+0.17%
- GOOGL$295.77−0.98%
- AMZN$266.66−0.29%
- META$641.69+2.90%
- TSLA$390.22−1.82%
- AVGO$347.01−4.76%
- AMD$534.06−8.75%
- MU$778.31−2.52%
Stock news
15 stories match “ROG”
Market narrative auditsMeta's $95 Billion AI Funding Plan Puts Shareholder Dilution in FocusThe company launched a smaller offering package and outlined a conditional stock-sale program. The shareholder cost depends on pricing and actual issuance. META · OptimistFi Research Desk · 
Market narrative auditsNebius Group N.V. (NASDAQ: NBIS) Commits $10 Million to AI BuildersThe European program broadens Nebius's developer funnel, but applicant and event counts do not yet show paid cloud demand. NBIS · OptimistFi Research Desk · 
Market narrative auditsBiotech2k Maps Insmed Incorporated (NASDAQ: INSM) TPIP Patent PathBiotech2k's patent test meets a live Phase 3 program: Insmed Incorporated (NASDAQ: INSM) has started three of four PALM studies, but rival patents reach 2042. INSM · OptimistFi Research Desk · 
Market narrative auditsPark Aerospace Corp. (NYSE: PKE) Expands Profit as Sales RiseQuarterly sales rose 26.9%, net income climbed 88.6%, and the cash balance increased. The next test is whether program demand can repeat at a larger base. PKE · OptimistFi Research Desk · 
Investor guidesWhy Is Tesla, Inc. (NASDAQ: TSLA) Stock Down 17% This Year?Vehicle deliveries recovered, but Tesla, Inc. (NASDAQ: TSLA) has yet to turn its much larger investment program into proportional profit and free-cash-flow growth. TSLA · OptimistFi Research Desk · 
Market narrative auditsViatris Inc. (NASDAQ: VTRS) Buys Pacira for $1.65 BillionThe deal values Pacira at 9.3 times trailing adjusted EBITDA and tests whether Viatris can buy growth without undoing its debt progress. VTRS · OptimistFi Research Desk · 
Investor guidesUroGen Pharma Ltd. (NASDAQ: URGN) Stock Is Down 12%: The Investment CaseZUSDURI is scaling fast enough to bring the business near operating break-even, while cash burn and financing claims still decide the equity case. URGN · OptimistFi Research Desk · 
Market narrative auditsCentury Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 BatchesFive clinical-scale runs now support consistent manufacturing, up from three in June. The program still has no human safety or efficacy data. IPSC · OptimistFi Research Desk · 
Market narrative auditsRogers Corporation (NYSE: ROG) Targets $1.5 Billion in SalesManagement's 2030 sales and margin targets require a sharp break from the company's recent revenue decline. The first checkpoints arrive well before the deadline. ROG · OptimistFi Research Desk · 
Market narrative auditsCoreWeave, Inc. (NASDAQ: CRWV) Capped Calls Don't End DilutionCapped calls can soften conversion dilution, but a separate 35 million-share program equals about 6.3% of the current common-share base. CRWV · OptimistFi Research Desk · 
Market narrative auditsPulse Biosciences, Inc. (NASDAQ: PLSE) Lines Up Cash for Its Next Clinical TestsAn $85 million share-sale program could fund development as a thyroid study reaches full enrollment. Shareholders need to weigh that progress against dilution. PLSE · OptimistFi Research Desk · 
Market narrative auditsAlphabet's Hassabis Backs AI Pacing as Capital Spending DoublesDemis Hassabis supports the direction of slower frontier progress, but Alphabet's latest filing still shows accelerating infrastructure investment. GOOGL · OptimistFi Research Desk ·
NBIS · OptimistFi Research Desk · 
INSM · OptimistFi Research Desk · 
VTRS · OptimistFi Research Desk · 
URGN · OptimistFi Research Desk · 
IPSC · OptimistFi Research Desk · 
CRWV · OptimistFi Research Desk · 
PLSE · OptimistFi Research Desk ·